Quinoline and thiazolopyridine allosteric inhibitors of MALT1

被引：13

作者：

Scott, David A. ^{[1
,2
]}

Hatcher, John M. ^{[1
,2
]}

Liu, Hongyan ^{[5
]}

Fu, Mingpeng ^{[5
]}

Du, Guangyan ^{[1
,2
]}

Fontan, Lorena ^{[3
]}

Us, Ilkay ^{[3
]}

Casalena, Gabriella ^{[3
]}

Qiao, Qi ^{[4
]}

Wu, Hao ^{[4
]}

Melnick, Ari ^{[3
]}

Gray, Nathanael S. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA

[2] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, 360 Longwood Ave, Boston, MA 02115 USA

[3] Cornell Univ, Div Hematol & Oncol, Dept Med, Weill Cornell Med, New York, NY 10021 USA

[4] Harvard Med Sch, Program Cellular & Mol Med, Boston Childrens Hosp, Boston, MA 02115 USA

[5] PepTech Shanghai Pharmaceut Corp, 388 Yindu Rd, Shanghai 200231, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2019年 / 29卷 / 14期

关键词：

MALT1; Protease inhibitors; Allosteric; B-cell lymphomas; PROTEASE;

D O I：

10.1016/j.bmcl.2019.05.040

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Quinolines and thiazolopyridines were developed as allosteric inhibitors of MALT1, with good cellular potency and exquisite selectivity. Mouse pharmacokinetic (PK) profiling showed these to have low in vivo clearance, and moderate oral exposure. The thiazolopyridines were less lipophilic than the quinolines, and one thiazolopyridine example was active in our hIL10 mouse pharmacodynamic (PD) model upon oral dosing.

引用

页码：1694 / 1698

页数：5

共 50 条

[21] An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient
Quancard, Jean
Klein, Theo
Fung, Shan-Yu
Renatus, Martin
Hughes, Nicola
Israel, Laura
Priatel, John J.
Kang, Sohyeong
Blank, Michael A.
Viner, Rosa I.
Blank, Jutta
Schlapbach, Achim
Erbel, Paul
Kizhakkedathu, Jayachandran
Villard, Frederic
Hersperger, Rene
Turvey, Stuart E.
Eder, Joerg
Bornancin, Frederic
Overall, Christopher M.
NATURE CHEMICAL BIOLOGY, 2019, 15 (03) : 304 - +
[22] Identification of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies
Yin, Wu
Zhe, Nie
Placzek, Andrew
Trzoss, Michael
Krilov, Goran
Feng, Shulu
Lawrenz, Morgan
Pelletier, Robert
Lai, George
Bell, Jeff
Calkins, David
Grimes, Mary
Tang, Wayne
McRobb, Fiona
Gerasyuto, Aleksey
Feher, Victoria
Mondal, Sayan
Jensen, Kristian
Wright, Hamish
Akinsanya, Karen
BLOOD, 2020, 136
[23] An allosteric MALT1 inhibitor as a molecular corrector for protein function rescuing in an immunodeficient patient
Fung, S. Y.
Quancard, J.
Klein, T.
Renatus, M.
Turvey, S. E.
Bornancin, F.
Overall, C. M.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1222 - 1223
[24] TARGETING MALT1 IN GLIOBLASTOMA
Azambuja, Juliana
Hu, Baoli
Lucas, Peter
McAllister-Lucas, Linda
PEDIATRIC BLOOD & CANCER, 2022, 69
[25] Discovery of orally bioavailable inhibitors of MALT1 with in vivo activity for psoriasis
Asaba, Ken Nunettsu
Okimura, Keiichi
Adachi, Yohei
Tokumaru, Kazuyuki
Goto, Yasufumi
Fujii, Shigeo
Watanabe, Akira
Sakai, Chizuka
Sakurada, Eri
Amikura, Kazutoshi
Aoki, Takumi
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 82
[26] Finally, MALT1 is a protease!
McAllister-Lucas, Linda M.
Lucas, Peter C.
NATURE IMMUNOLOGY, 2008, 9 (03) : 231 - 233
[27] MALT1 Inhibitors May Potentially Treat Lymphomas and Autoimmune Disorders
Abdel-Magid, Ahmed F.
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (03): : 205 - 206
[28] The Paracaspase MALT1 in Cancer
Solsona, Beatriz Gomez
Schmitt, Anja
Schulze-Osthoff, Klaus
Hailfinger, Stephan
BIOMEDICINES, 2022, 10 (02)
[29] Finally, MALT1 is a protease!
Linda M McAllister-Lucas
Peter C Lucas
Nature Immunology, 2008, 9 : 231 - 233
[30] The paracaspase MALT1 in psoriasis
Hailfinger, Stephan
Schulze-Osthoff, Klaus
BIOLOGICAL CHEMISTRY, 2021, 402 (12) : 1583 - 1589

← 1 2 3 4 5 →